Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
KEMPTEN, Germania, May 05, 2023 (GLOBE NEWSWIRE) -- ABT Sportsline, azienda leader nel tuning di veicoli del Gruppo Audi e VW, entusiasma i suoi fan con straordinari modelli speciali. L'ultimo...
-
KEMPTEN, Allemagne, 05 mai 2023 (GLOBE NEWSWIRE) -- ABT Sportsline, le préparateur principal de véhicules Audi et VW, fascine ses fans avec des modèles spéciaux extraordinaires. L’ABT RS6 Legacy...
-
Dublin, May 04, 2023 (GLOBE NEWSWIRE) -- The "Agriculture Tires Market - Global Industry Analysis (2019 - 2020), Growth Trends, and Market Forecast (2021 - 2027)" report has been added to ...
-
KEMPTEN, Germany, May 04, 2023 (GLOBE NEWSWIRE) -- ABT Sportsline, führender Veredler für Fahrzeuge des Audi- und VW-Konzerns, begeistert seine Fans immer wieder mit außergewöhnlichen...
-
KEMPTEN, Germany, May 04, 2023 (GLOBE NEWSWIRE) -- ABT Sportsline, leading tuner for vehicles of the Audi and VW Group, inspires its fans with extraordinary special models. The latest example is the...
-
SCOTTSDALE, Ariz., May 03, 2023 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced it has a number of quick move-in homes available now...
-
Toronto, May 02, 2023 (GLOBE NEWSWIRE) -- Toronto, Ontario - AutoLeap announced today its direct integration with TireHub, a renowned national tire distributor. Shop owners using AutoLeap can...
-
WASHINGTON, April 28, 2023 (GLOBE NEWSWIRE) -- The Global Self-Healing Materials Market is valued at USD 1.4 Billion in 2022 and is projected to reach a value of USD 6.75 Billion by 2030 at a CAGR...
-
Acquisition builds on Blink Mobility’s experience partnering with local communities and municipalities and Envoy’s innovative platform and business models working with leading hotels, apartments,...
-
The ALITHIOS open-label extension study showed continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS) patients was associated with reduced risk of...